Physician profile
Michelle E Prager
NPI 1962871202
$39,182.74
in general payments reported to CMS, 2019-2025
8 companies · $15.95 in 2025
The $15.95 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,610 · 2022: $311 · 2023: $35K · 2024: $1,428 · 2025: $15.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Travel and Lodging: $12K · Consulting Fee: $2,700 · Food and Beverage: $1,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,517.50 |
| Travel and Lodging | $12,458.53 |
| Consulting Fee | $2,700.00 |
| Food and Beverage | $1,584.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $17,155.38 | 2021-2024 | Verzenio |
| Gilead Sciences, INC. | $14,279.33 | 2022-2024 | Trodelvy |
| Pfizer INC. | $6,793.79 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $500.00 | 2023 | |
| Daiichi Sankyo INC. | $251.06 | 2021-2023 | Enhertu |
| Puma Biotechnology, INC. | $133.47 | 2021-2023 | |
| Myriad Genetic Laboratories, INC. | $53.76 | 2022-2023 | Myrisk |
| Philips North America LLC | $15.95 | 2025 | Eagle Eye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Prager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.